EMPA-Kidney Archives - Medical Conferences

Empagliflozin reduces risk of kidney disease progression and CV events in patients with CKD

Presented By

Prof. David Preiss, University of Oxford, UK

Trial

Phase 3, EMPA-KIDNEY

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 13:56

Presented By

Dr William Herrington, University of Oxford, UK

Trial

Phase 3, EMPA-KIDNEY

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:53

Presented By

Robert van den Heuvel, Medicom

Conference

AHA 2022

28 November 2022 13:03

Presented By

Prof. Faiez Zannad, University of Lorraine, France

Trial

EMPEROR-Reduced; DAPA=HF; DAPA-CKD; EMPA-Kideney

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 09:39